Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Best Peptides for Alzheimer's Prevention: Mechanism Comparison

Thymalin Immune modulation. Upregulates CD4+ T-cells, suppresses neuroinflammatory cytokines (TNF-α, IL-6) Indirect. Peripheral immune signals cross BBB; peptide itself does not 5–10 mg SC daily × 10–20 days (human equivalent ~0.16 mg/kg) Preclinical animal mo

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Thymalin
  • Immune modulation. Upregulates CD4+ T-cells, suppresses neuroinflammatory cytokines (TNF-α, IL-6)
  • Indirect. Peripheral immune signals cross BBB; peptide itself does not
  • 5–10 mg SC daily × 10–20 days (human equivalent ~0.16 mg/kg)
  • Preclinical animal models; limited human trials in aging populations
  • Best for immune-driven neurodegeneration; addresses root inflammation rather than symptoms
  • Cerebrolysin
  • Neurotrophic support. BDNF/NGF analogs bind TrkB receptors, promote dendritic spine formation
  • Moderate. Requires IV administration; peptide fragments penetrate via active transport
  • 10–30 mL IV daily × 20 days, cycled every 6–8 weeks
  • Multiple Phase III trials; 2025 meta-analysis of 18 studies
  • Most evidence in established Alzheimer's; modest cognitive stabilization in mild-to-moderate cases
  • P21
  • Synaptic plasticity. Enhances hippocampal long-term potentiation, increases dendritic spine density
  • High. Lipophilic hexapeptide crosses BBB passively; measurable CNS levels in 90 min
  • 1–5 mg/kg SC 3–5×/week (rat models; human equivalent ~0.16–0.8 mg/kg)
  • Robust preclinical data (UC Irvine); no published human trials yet
  • Strongest preclinical neurogenesis data; limited to research settings until human trials complete
  • Dihexa
  • HGF/c-Met signaling. Promotes synaptogenesis and neuronal survival pathways
  • Moderate. Crosses BBB but lower penetration than P21; oral bioavailability ~40%
  • 0.5–2 mg/kg SC or 2–5 mg/kg oral 3–5×/week
  • Preclinical only; promising TBI and stroke models
  • Potent synaptogenic activity but less studied than P21 in Alzheimer's models specifically

Related resources

More comparisons